upcarta
  • Sign In
  • Sign Up
  • Explore
  • Search

Manni Mohyuddin

healthcare.utah.edu
1 Follower
community-curated profile

Cancer doctor at @huntsmancancer with interest in myeloma, supportive care, end of life, cost-effective/evidence-based care and med-ed. No COI. Views own.

Overview Posts Content Recommendations
Popular Recent
  • Tweet
  • Paper
  • Podcast episode
Manni Mohyuddin @ManniMD1 · Feb 10, 2023
  • From Twitter

Dr Costa- loved this thread. The power calculations reflected a much higher performance of the control arm (9 months) compared to what we saw (4 months). Why do you think that was the case?

Tweet Jan 6, 2023
Now that horse is out of the barn... a few important points about KARMMA-3 #mmsm @paurotero @NBahlis @MyelomaTeacher #myeloma 1/X - First randomized phase 3 trial to show clinical benefit for Car-T cell therapy in MM. That is HUGE. twitter.com/Rahul
by Luciano J Costa
Post Add to Collection Mark as Completed
Recommended by 1 person
1 mention
Share on Twitter Repost
Manni Mohyuddin @ManniMD1 · Jan 24, 2023
  • From Twitter

Excellent thread by @bdermanmd on ALLO-715, an allogeneic BCMA targeting CAR T cell therapy! #mmsm

Tweet Jan 24, 2023
Results of ALLO-715, an allogeneic BCMA-targeting CAR T cell therapy are published. Novel features to this product: ‼️ Has rituximab kill switch ‼️ Knockout of the T cell receptor alpha constant (TRAC) to reduce GVHD risk ‼️ Knockout CD52 /1 #mmsm w
by Ben Derman
Post Add to Collection Mark as Completed
Recommended by 1 person
1 mention
Share on Twitter Repost
Manni Mohyuddin @ManniMD1 · Jan 23, 2023
  • From Twitter

This was an excellent reminder of why I love our pharmacists so much- and am thankful to have them in clinic every single day. @KLratermann Great podcast! #mmsm

Podcast episode Jan 18, 2023
Episode 043: Myeloma Series, Pt.4 - Myeloma Pharmacology
by Kelley Louise Julian and 3 others
Post Add to Collection Mark as Completed
Recommended by 1 person
1 mention
Share on Twitter Repost
Manni Mohyuddin @ManniMD1 · Jan 21, 2023
  • From Twitter

A very thoughtful thread by @rajshekharucms on this trial, and how to think through maintenance trials in general! #mmsm

Tweet Jan 21, 2023
Although a negative trial, the recently published Vorinostat-Len (VR) vs Len (R) analysis of Myeloma XI RCT had some important learning points🧵#mmsm @profghjackson @DrGarethMorgan1 tinyurl.com/ysxu446k
by Raj Chakraborty
Post Add to Collection Mark as Completed
Recommended by 1 person
1 mention
Share on Twitter Repost
Manni Mohyuddin @ManniMD1 · Jan 21, 2023
  • From Twitter

A very thoughtful article on sequencing BCMA therapies by @Mohty_EBMT in @BloodJournal , accompanying a small 24 patient trial (only 20 of which made it to cilta-cel) in those previously exposed to BCMA therapy. #mmsm

Paper
Sequencing anti-BCMA therapies in myeloma
by Mohamad Mohty
Post Add to Collection Mark as Completed
Recommended by 1 person
1 mention
Share on Twitter Repost
Manni Mohyuddin @ManniMD1 · Jan 18, 2023
  • From Twitter

Great work, Dr Costa!

Paper
Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma
by Luciano J Costa
Post Add to Collection Mark as Completed
Recommended by 1 person
1 mention
Share on Twitter Repost
Manni Mohyuddin @ManniMD1 · Jan 8, 2023
  • From Twitter

Read this short paper and then think of the smoldering myeloma landscape. It’ll blow your mind! #mmsm

Paper
Medicine and Risk Transfer
by Nassim Nicholas Taleb
Post Add to Collection Mark as Completed
Recommended by 1 person
1 mention
Share on Twitter Repost
Manni Mohyuddin @ManniMD1 · Dec 26, 2022
  • From Twitter

What an excellent and nuanced discussion on lymphoma abstracts from ASH22 with ⁦@tobyeyre82⁩ ⁦@Eddie_Cliff⁩ ⁦@rajshekharucms⁩ on ⁦@BloodCancerTalk⁩ Very informative- even as a myeloma doctor gave me lots to think about.

Podcast episode Dec 21, 2022
ASH22 Recap: Lymphoma and CLL
by Raj Chakraborty and 2 others
Post Add to Collection Mark as Completed
Recommended by 1 person
1 mention
Share on Twitter Repost
Manni Mohyuddin @ManniMD1 · Dec 11, 2022
  • From Twitter

Great thread and work Urvi. I do think though that the effect size of dietary interventions is likely going to be extremely modest when it comes to disease activity. I do not think changes in stool butyrate level are a meaningful endpoint in itself, especially for mgus.

Tweet Dec 5, 2022
Dietary research in blood cancers is an unmet need. Excited that #ASH22 has a special scientific symposium dedicated to Building Dietary Evidence for Hematologic Malignancies this year! Hope you can attend @ASH_hematology @MSKCancerCenter #diet #mmsm
by Urvi Shah
Post Add to Collection Mark as Completed
Recommended by 1 person
1 mention
Share on Twitter Repost
  • upcarta ©2025
  • Home
  • About
  • Terms
  • Privacy
  • Cookies
  • @upcarta